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PURPOSE. To evaluate the relationship between retinal vascular caliber and AMD in patients
with AIDS.
METHODS. Participants enrolled in the Longitudinal Study of the Ocular Complications of AIDS
had retinal photographs taken at enrollment. Retinal vascular caliber (central retinal artery
equivalent [CRAE] and central retinal vein equivalent [CRVE]) and intermediate-stage AMD
were determined from these retinal photographs. Photographs were evaluated by graders at a
centralized reading center, using the Age-Related Eye Disease Study grading system for AMD
and semiautomated techniques for evaluating retinal vascular caliber.
RESULTS. Of the 1171 participants evaluated, 110 (9.4%) had AMD and 1061 (90.6%) did not.
Compared with participants without AMD, participants with AMD had larger mean CRAEs
(151 6 16 lm versus 147 6 16 lm; P ¼ 0.009) and mean CRVEs (228 6 24 lm versus 223 6
25 lm; P ¼ 0.02). The unadjusted differences were: CRAE, 4.3 lm (95% confidence interval
[CI] 1.1–7.5; P ¼ 0.009) and CRVE, 5.5 lm (95% CI 0.7–10.3; P ¼ 0.02). After adjustment for
age, race/ethnicity, sex, human immunodeficiency syndrome (HIV) transmission category,
smoking, enrollment and nadir CD4þ T cells, and enrollment and maximum HIV load, the
differences between patients with and without AMD were as follows: CRAE, 5.4 lm (95% CI
2.3–8.5; P ¼ 0.001) and CRVE, 6.0 lm (95% CI 1.4–10.6; P ¼ 0.01).
CONCLUSIONS. In patients with AIDS, AMD is associated with greater retinal arteriolar and
venular calibers, suggesting a role for shared pathogenic mechanisms, such as persistent
systemic inflammation.
Keywords: acquired immunodeficiency syndrome, age-related macular degeneration, retinal
vascular caliber
AMD is a leading cause of visual impairment and blindness inpersons older than 65 years.1,2 Although there are regional
differences in the prevalence of AMD, globally, it is estimated
that the number of persons with AMD will be 196 million in
2020 and 288 million by 2040.3 AMD typically is staged as early,
intermediate, or late. Early-stage AMD consists of small drusen.
Intermediate-stage AMD consists of extensive medium-size
drusen or any large drusen, with or without pigment changes.
Late-stage AMD is defined by the presence of either choroidal
neovascularization or geographic atrophy.4–7 Antiretroviral-
treated, immune-restored, human immunodeficiency virus
(HIV)-infected persons have a marked reduction in the
incidence of opportunistic infections and a substantially
increased life span compared with those from the era before
modern combination antiretroviral therapy (cART).8–11 Despite
these improvements, antiretroviral-treated, immune-restored,
HIV-infected persons have a substantially shortened life span
compared with similarly aged, HIV-uninfected peers, which
largely is due to an increased risk of non-AIDS diseases
associated with aging (e.g., cardiovascular disease, non-AIDS
cancers, metabolic diseases, and neurocognitive decline).12–16
This increased risk of age-related diseases suggests that
antiretroviral-treated, immune-restored, HIV infection is associ-
ated with an ‘‘accelerated and/or accentuated aging’’ pheno-
type.12,16 Consistent with this accentuated aging, patients with
AIDS have an approximately 4-fold increased age- and sex-
adjusted prevalence of intermediate-stage AMD and an approx-
imately 1.75-fold increased race- and sex-adjusted incidence of
intermediate-stage AMD when compared with that in HIV-
uninfected cohorts.17,18 Patients with AIDS also have retinal
vascular calibers consistent with those of HIV-uninfected
persons who are on average 10 years older, again consistent
with an accelerated/accentuated aging phenotype.19 Therefore,
we investigated the relationship between AMD and retinal
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vascular caliber in persons with AIDS enrolled in the
Longitudinal Study of the Ocular Complications of AIDS
(LSOCA).
METHODS
LSOCA was a prospective, observational, cohort study of
patients with AIDS in the era of modern cART.20,21 Enrollment
began on September 1, 1998, and was completed on July 31,
2011. All participants had AIDS diagnosed according to the
1993 Centers for Disease Control and Prevention revised
criteria for the diagnosis of AIDS.22 Recruitment occurred at 19
clinical centers throughout the United States, typically located
in urban centers with a large HIV-infected population.20
Participants with and without ocular opportunistic infections
were recruited.
At enrollment, all participants gave a detailed medical and
HIV-related disease history; relevant findings were confirmed
from the medical record. Fifty to 60-degree retinal photograph
of the disc and macula were taken at enrollment, as previously
described.17–21 Laboratory testing at enrollment included
hematology and blood chemistry, blood CD4þ T cells, the
amount of circulating HIV RNA in the blood (HIV load), and the
presence of antibodies to hepatitis C.20,21
Approval for the study and its procedures was obtained
from the institutional review boards of the individual
participating clinical centers and the three resource centers
(chairman’s office, coordinating center, and reading center).
Written, informed consent was obtained from all participants.
The study was conducted in accordance with the principles of
the Declaration of Helsinki.
Grading of Retinal Photographs
Photographs were graded at the Studies of the Ocular
Complications of AIDS (SOCA) Reading Center at the
University of Wisconsin from stereoscopic color photographs
of the macula obtained at enrollment. Photographers and
camera systems were certified for SOCA photographic
procedures by reading center personnel. Images were graded
either from 35-mm film, mounted in typical slide mounts and
viewed on a light box with a Donaldson 5X stereoscopic
viewer, or from digital images displayed on calibrated
computer monitors and viewed with a stereoscopic viewer
(PS Manufacturing, Portland, OR, USA). The Early Treatment
Diabetic Retinopathy Grid, measuring 7.2 mm on the retina,
was placed on film slides using an acetate overlay sized for the
camera type and degree of view.5,17,18 Digital image grading
used software tools to calibrate and locate the grid.7,17,18
Approximately 10% of the enrollment photographs were
digital. Grading of digital images at a reading center for AMD
has been demonstrated to be comparable with that of film
images.23 Fundus photographs were graded for the features of
intermediate-stage AMD, including the presence, size, and area
of drusen, and the presence and area of pigmentary
abnormalities. Grading procedures were based on the Age-
Related Eye Disease Study system for classifying AMD from
retinal photographs.6,7 Graders were masked as to clinical
information. The outcome of interest was the presence of
intermediate-stage AMD, defined as at least one large druse
(>150 lm using modern estimates of the average disc size or
>125 lm using the traditional estimate) or extensive medium-
sized drusen with pigment abnormalities.6,24 Quality control
was provided by a resampling and regrading of 10% of the
photographs by the reading center project ophthalmologist
(RPD).
Retinal vascular indices were determined in a semiauto-
mated manner as previously described.19,25 Briefly, the six
largest arterioles and venules in a ring-shaped area located
between 0.5 and 1.0 disc diameter from the optic margin were
identified. Computer software measured the caliber of these
individual vessels, then combined them into two summary
variables for the eye: the projected caliber sizes of the central
retinal artery equivalent (CRAE) and of the central retinal vein
equivalent (CRVE). Because drusen are difficult to evaluate in
the face of extensive retinal necrosis and scarring from
cytomegalovirus (CMV) retinitis, eyes with ocular opportunis-
tic infections were not graded, and these participants were not
included in the AMD study.26
Statistical Methods
The association of the presence of AMD at baseline with
characteristics of the study population was assessed using the
v2 test for categorical variables, the t-test for normally
distributed continuous variables, and the Wilcoxon rank sum
test for non-normally distributed continuous variables.27
Multiple linear regression was used to assess relationships of
CRAE and CRVE with presence of AMD in three models:
unadjusted, adjusted for age, and adjusted for age and other
baseline covariates. P values were two-sided and nominal.
Statistical analyses were conducted with SAS/STAT, version 9.3
(SAS Institute, Inc., Cary, NC, USA) and Stata version 15.0
(StataCorp, College Station, TX, USA) software packages.
RESULTS
Characteristics of the Study Population
Of the 2392 participants enrolled in LSOCA, 535 had an
intraocular opportunistic infection (primarily CMV retinitis)
and could not be assessed for AMD, leaving 1857 participants.
Of these, 1583 were assessed for AMD from the enrollment
photographs. Of these 1583 participants, 1171 also were
assessed for the retinal vascular caliber from enrollment
photographs. The 1171 participants assessed for both AMD
and retinal vascular caliber form the study population. Of these
1171 patients, 110 (9.4%) had intermediate-stage AMD, and
1061 (90.6%) did not.
Baseline (enrollment) characteristics of the study popula-
tion and of participants with and without AMD are listed in
Table 1. There were no significant differences between
participants with and without AMD with respect to sex,
race/ethnicity, time since AIDS diagnosis, enrollment CD4þ T
cells, nadir CD4þ T cells before enrollment, HIV load at
enrollment, maximum HIV load before enrollment, use of
cART, and comorbidities. Participants with AMD were older
(mean age 47.0 6 8.3 years) than those without AMD (mean
age 42.6 6 8.0 years, P < 0.0001) and appeared to have a
greater proportion of participants whose HIV transmission
category was either injection drug use or heterosexual
transmission (P ¼ 0.04; see Table 1).
Retinal Vascular Caliber
Participants with AMD had larger CRAE and CRVE than
participants without AMD (Table 1; Figs. 1, 2). The mean (6
SD) CRAEs for participants with and without AMD were 151 6
16 lm and 147 6 16 lm, respectively (P < 0.009). The mean
(6 SD CRVEs for participants with and without AMD were 228
6 24 lm and 223 6 25 lm, respectively (P¼ 0.02). The mean
CRAE and CRVE declined with age for participants with and
without AMD, but were consistently larger for participants
with AMD (Figs. 1, 2, respectively). The adjusted differences in
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CRAE and CRVE between those with and without AMD were
even greater in the multiple linear regression analyses (Table
2). In the model adjusted for age, race/ethnicity, sex, HIV
transmission category, smoking, enrollment and before enroll-
ment nadir CD4þ T cells, enrollment and prior maximum HIV
load, the difference in mean CRAE between those with and
without AMD was 5.4 lm (95% confidence interval [CI] 2.3–
8.5; P ¼ 0.001), and the difference in mean CRVE between
TABLE 1. Univariate Analysis of Baseline Patient Characteristics and Prevalent Intermediate-stage AMD in Patients With AIDS Enrolled in LSOCA
No AMD AMD Total P
Number of patients 1061 110 1171
Demographics
Age, y, mean 6 SD 42.6 6 8.0 47.0 6 8.3 43.0 6 8.2 <0.0001
Sex, % men 81.1 76.4 80.6 0.25
Race/ethnicity, % 0.69
White, non-Hispanic 48.4 43.6 48.0
African American 33.6 35.4 33.7
Hispanic 15.0 16.4 15.1
Other 3.0 4.6 3.2
Smoking history, % 0.58
Current 41.2 37.8 40.9
Former 35.8 34.2 35.6
Never 23.0 28.0 23.4
AIDS history
Time since AIDS diagnosis, y, median [25th, 75th percentile] 4.3 [1.7, 6.9] 4.4 [1.1, 7.2] 4.3 [1.6, 7.0] 0.92
HIV transmission category, % 0.04
Injection drug use (IDU) 13.7 15.4 13.8
Male-to-male sexual contact and no IDU 55.6 43.6 54.5
Heterosexual contact 25.5 37.3 26.6
Other 5.2 3.6 5.0
Immunology and virology
Enrollment CD4þ T cells, cells/lL, median [25th, 75th percentile] 189 [77, 345] 189 [91, 295] 189 [79, 342] 0.88
Nadir prior CD4þ T cells, cells/lL, median [25th, 75th percentile] 40 [12, 107] 49 [20, 120] 41 [13, 110] 0.14
Enrollment HIV load, log10(copies/mL), mean 6 SD 3.3 6 1.4 3.4 6 1.4 3.3 6 1.4 0.73
Maximum prior HIV load, log10(copies/mL), mean 6 SD 5.0 6 1.0 5.1 6 0.9 5.0 6 1.0 0.76
HIV treatment
cART* at enrollment, % 82.4 85.4 82.7 0.51
Comorbidities at enrollment, %
Diabetes 8.3 9.1 8.4 0.77
Hyperlipidemia 21.1 20.0 21.0 0.80
Elevated serum creatinine 5.3 5.4 5.3 0.94
Hypertension 18.7 22.7 19.0 0.30
Cardiovascular disease 13.3 18.5 13.7 0.19
Hepatitis C infection, % seropositive 21.6 22.3 21.7 0.86
Retinal vascular caliber, mean 6 SD
CRAE, lm 147 6 16 151 6 16 147 6 16 0.009
CRVE, lm 223 6 25 228 6 24 223 6 25 0.02
* cART ¼ combination therapy including at least one potent antiretroviral drug (e.g., a protease inhibitor).
FIGURE 1. Scatterplot and regression lines of CRAE by age in patients
with AIDS with and without AMD.
FIGURE 2. Scatterplot and regression lines of CRVE by age in patients
with AIDS with and without AMD.
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those with and without AMD was 6.0 lm (95% CI 1.4–10.6; P¼
0.01).
DISCUSSION
We previously reported that patients with AIDS had an
approximately 4-fold increased prevalence of intermediate-
stage AMD and an approximately 1.75-fold increased incidence
of intermediate-stage AMD, consistent with the accelerated/
accentuated aging phenotype present in antiretroviral-treated,
immune-restored, HIV-infected persons.17,18 In this study, we
demonstrate that persons with AIDS with AMD have larger
retinal arteriolar and venular calibers than HIV-infected
persons without AMD. Previous work in HIV-uninfected
populations has demonstrated several risk factors for changes
in retinal vascular caliber.28–34 Older age is associated with
narrower retinal vascular caliber, and hypertension is associ-
ated with narrower retinal arterioles; conversely, cigarette
smoking is associated with wider retinal arterioles and venules,
although some studies have reported a greater effect on
venules.28–30 Biomarkers of systemic inflammation consistently
are associated with wider retinal venules.28,29,31,32 The results
of studies of HIV-uninfected persons with AMD have been
variable, with one study showing only wider retinal arterioles
and another study only wider retinal venules.28,29,33,34 In our
study, both retinal arteriolar caliber and venular caliber were
greater among persons with AMD. This effect was consistent
across age, and adjustments for baseline parameters only
increased the estimated difference. Our study did show an age-
related decline in both CRAE and CRVE in both persons with
and without AMD, as is seen in HIV-uninfected persons, but the
CRAE and CRVE consistently were larger among patients with
AMD than those without.
Antiretroviral-treated, immune-restored, HIV-infected per-
sons have immunologic changes similar to those seen in HIV-
uninfected persons older than 70 years, a phenomenon
sometimes termed immunosenescence.12,16 Antiretroviral-
treated, immune-restored, HIV-infected persons are character-
ized by a state of chronic immune activation with ongoing
systemic inflammation.12,16,35 Studies in HIV-uninfected per-
sons demonstrate that systemic inflammation is a risk factor for
AMD.36–39 Therefore, the increased retinal venular caliber in
HIV-infected persons with AMD may relate to the common role
of systemic inflammation in the pathogenesis of AMD and in
altered retinal vascular caliber. Nevertheless, it also is possible
that other, unobservable factors are responsible for both the
occurrence of AMD and vascular dilation in these patients.
Caution should be taken in interpreting our data. Although
the AMD lesions seen in the LSOCA population are clinically
and photographically identical to those seen in HIV-uninfected
populations, we do not have histology to confirm the nature of
the lesions. Caution also should be taken in extrapolating our
data to all HIV-infected persons. The LSOCA cohort enrolled
only persons with AIDS and not earlier stages of HIV
infection.20,21 The nadir CD4þ T cells were very low, even
though many participants had substantial immune recovery by
enrollment. The effects of such levels of immune deficiency on
subsequent immune activation and systemic inflammation may
be different from those seen in HIV-infected patients who
never reach this level of immune deficiency. As such, the
prevalence and incidence of AMD in HIV-infected patients with
earlier stages of HIV infection remain uncertain. Nevertheless,
because of late diagnosis and difficulties in completely
suppressing HIV replication among all patients, many individ-
uals with HIV infection will present with or progress to
AIDS,40,41 so that there remains a population of HIV-infected
patients who will progress to AIDS and for whom these results
are relevant. Furthermore, the LSOCA cohort is similar to the
AIDS epidemic in the United States in terms of demographic
and other characteristics,20 suggesting some degree of
generalizability to patients with AIDS. Finally, we only could
analyze (and adjust for) those factors where we had data from
the LSOCA cohort study. As such, it is possible that other,
unobservable factors may contribute to both AMD and retinal
vascular dilation in this population.
In sum, LSOCA data demonstrate increased retinal vascular
caliber, both CRAE and CRVE, in persons with AIDS and AMD.
The relationship of systemic inflammation to AMD in HIV-
uninfected persons and to increased retinal venular cali-
ber,31,32,36–39 as well as the state of chronic immune activation
and systemic inflammation among antiretroviral-treated HIV-
infected persons,12,16,35 suggest a possible common pathoge-
netic role for inflammation in both of these findings.
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